Latest from the FDA

• Are Healthcare Antiseptics Toxic to Staff and Patients? The FDA is embarking on an initiative to require data from manufacturers on the effectiveness and potential long-term toxicity of frequently used healthcare antiseptics.
  FDA Expert Commentaries and Interviews, June 16, 2015
• Montelukast's Underrecognized Adverse Drug Events Leukotriene inhibitors, montelukast in particular, have been linked to numerous reports of neuropsychiatric events. What should clinicians know?
  FDA Expert Commentaries and Interviews, March 02, 2015
• FDA Updates Labels for Pregnant and Breastfeeding Women Find out how new FDA rules for prescription drugs will help you better determine risks for pregnant and breastfeeding women.
  FDA Expert Commentaries and Interviews, January 09, 2015
• Targeting Drugs for Rare Diseases   Marshall Summar speaks with FDA director of the Office of Orphan Products Development, Gayatri Rao, about progress in diagnostics and therapeutics for rare diseases.
  FDA Expert Commentaries and Interviews, November 25, 2014
• Responding to Ebola: The View From the FDA The FDA has ramped up its efforts to support product development, production, and availability as part of a massive international response to the ongoing Ebola outbreak.
  FDA Expert Commentaries and Interviews, August 20, 2014
• FDA Approval 2.0: Dr. Kandzari Interviews Dr. Bill Maisel   Dr. Kandzari interviews Deputy Director of Science for CDRH, Dr. Bill Maisel, on strategies to expedite FDA approval while maintaining scientific rigor.
  FDA Expert Commentaries and Interviews, April 28, 2014
• The New Food Labels: Information Clinicians Can Use The FDA has proposed major updates to the Nutrition Facts label on packaged foods. What are the key changes that will help clinicians educate their patients about healthy food choices?
  FDA Expert Commentaries and Interviews, April 09, 2014
• FDA's Rare Disease Program: A Rare Opportunity to Help Kids The first drug to come out of the FDA's rare pediatric disease priority review voucher program offers hope for patients with a rare progressive type of lysosomal storage disease.
  FDA Expert Commentaries and Interviews, March 18, 2014
• Critical Intravenous Solution Shortages Demand during a busy influenza season is one factor underlying the current nationwide shortage of intravenous solutions. Medscape spoke with the FDA about this issue and its efforts to mitigate it.
  FDA Expert Commentaries and Interviews, February 20, 2014
• Preventing Teen Tobacco Use: An Interview With the FDA The FDA has launched an ambitious campaign to prevent teens from initiating tobacco use. On the basis of extensive research, they have good reason to be optimistic that this one will work.
  FDA Expert Commentaries and Interviews, February 10, 2014
• Acetaminophen, Opioids, and Safety Prescribers have been asked to avoid use of combination opioid products with more than 325 mg of acetaminophen. What are the data behind this decision?
  FDA Expert Commentaries and Interviews, February 05, 2014
• Redefining 'Latex-Free' Current use of the term 'latex-free' in medical product labeling may give users with a natural rubber latex allergy a false sense of security. How will new draft guidance from the FDA help?
  FDA Expert Commentaries and Interviews, January 23, 2014
• Removing Trans Fats From Foods: The FDA's View The FDA has recently proposed eliminating artificial trans fats from all foods. What are the implications?
  FDA Expert Commentaries and Interviews, November 25, 2013
• Drugs and the Breastfeeding Mother: A New Clinical Report Out with the old 'alphabet letters' for classifying drugs in pregnancy and lactation, and in with a new system.
  FDA Expert Commentaries and Interviews, October 29, 2013
• Breast Implants: The View From the FDA Medscape spoke with 2 experts from the FDA about safety issues with breast implants.
  FDA Expert Commentaries and Interviews, July 17, 2013
• Choosing a Generic Antidepressant With one generic bupropion formulation recently withdrawn, how can clinicians best select from among the remaining options?
  FDA Expert Commentaries and Interviews, February 04, 2013
• Flu and the FDA: An Interview With Margaret A. Hamburg, MD The FDA Commissioner discusses influenza prevention and management, including concerns about antiviral shortages and appropriate use in infants.
  FDA Expert Commentaries and Interviews, January 23, 2013
• Telling the FDA: Why Contact Lens Adverse Events Matter The FDA requests that healthcare professionals report adverse events resulting from the use of contact lenses. Learn why it's important to report them and how to do so.
  FDA Expert Commentaries and Interviews, November 14, 2012
• Decorative Contact Lenses: Truly Frightening Decorative contact lenses are widely used, especially at Halloween. Dr. Michelle Tarver discusses the risks posed by these often misused devices.
  FDA Expert Commentaries and Interviews, October 24, 2012
• Contact Lenses: The Risks You Need to Know Although convenient, contact lenses can pose serious risks if not used and cared for properly. Dr. Bernard Lepri offers practical advice to reinforce to your contact lens-wearing patients.
  FDA Expert Commentaries and Interviews, October 24, 2012